Table 1 Demographic and clinical characteristics of patients
Characteristic | All patients (n = 343) | Starting dose < 40 mg (*) (n = 206) | Starting dose 40 mg (**) (n = 137) | p value |
|---|---|---|---|---|
Age (years) | ||||
Mean ± SD | 63.2 ± 9.7 | 64.0 ± 9.6 | 61.9 ± 9.8 | 0.056a |
≥ 65 years old | 152 (44.3) | 98 (47.6) | 54 (39.4) | 0.136b |
< 65 years old | 191 (55.7) | 108 (52.4) | 83 (60.6) | |
Sex | ||||
Male | 194 (56.6) | 113 (54.9) | 81 (59.1) | 0.435b |
Female | 149 (43.4) | 93 (45.1) | 56 (40.9) | |
ECOG performance status at diagnosis | ||||
PS 0–1 | 319 (93.0) | 193 (93.7) | 126 (92.0) | 0.541b |
PS 2–3 | 24 (7.0) | 13 (6.3) | 11 (8.0) | |
Smoking history | ||||
Nonsmoker/former smoker | 249 (72.6) | 148 (71.8) | 101 (73.7) | 0.713b |
Current smoker | 94 (27.4) | 58 (28.2) | 36 (26.3) | |
Stage | ||||
IIIB/IIIC | 19 (5.5) | 7 (3.4) | 5 (3.6) | 0.955b |
Recurrence | 12 (3.5) | 12 (5.8) | 7 (5.1) | |
IV | 312 (91.0) | 187 (90.8) | 125 (91.2) | |
Sites of Metastasis | ||||
Brain | 87 (25.4) | 55 (26.7) | 32 (23.4) | 0.486b |
Liver | 33 (9.6) | 18 (8.7) | 15 (10.9) | 0.496b |
EGFR mutations | ||||
Del 19 | 161 (46.9) | 93 (45.1) | 68 (49.6) | 0.716b |
L858R | 90 (26.2) | 56 (27.2) | 34 (24.8) | |
Uncommon mutations | 92 (26.8) | 57 (27.7) | 25 (25.5) | |